Athira Pharma, INC

LeonaBio reported first quarter 2026 financial results, highlighting progress in its Phase 3 lasofoxifene trial for metastatic breast cancer and upcoming Phase 2 study for ATH-1105 in ALS.

LeonaBio, Inc. (formerly Athira Pharma) has acquired exclusive global rights to lasofoxifene, a Phase 3 metastatic breast cancer candidate, backed by up to $236 million in financing.

LeonaBio, Inc. reported full year 2025 financial results, highlighted a strategic shift with the acquisition of a Phase 3 breast cancer drug license, and secured $90 million in private placement financing.

LeonaBio, Inc. stockholders approved a new 2026 Equity Incentive Plan and a significant increase in authorized common stock, alongside warrant exercises.

Athira Pharma rebrands as LeonaBio, Inc., changes ticker to LONA, and updates CFO severance terms, signaling a strategic shift towards late-stage oncology and neurodegenerative assets.

Athira Pharma has announced a $90 million private placement and an exclusive global license for late-stage breast cancer drug lasofoxifene, diversifying its pipeline and extending its cash runway into 2028.

Athira Pharma reports reduced net loss and operating expenses in Q3 2025, driven by a strategic shift to ATH-1105 development and a workforce reduction, while exploring strategic alternatives.

Athira Pharma reports reduced losses and operating expenses in Q2 2025, pivoting its R&D focus to ATH-1105 for ALS after its prior lead candidate failed to meet endpoints.

Athira Pharma announces Q1 2025 financial results, highlighting a net loss of $9.1 million and a strategic shift towards advancing the clinical development of ATH-1105 for neurodegenerative diseases.

Athira Pharma announced its Q3 2024 results, highlighted by a strategic shift to focus on ATH-1105 development and a workforce reduction, while pausing further development of fosgonimeton.

Athira Pharma has filed an amendment to its quarterly report to include previously omitted exhibits related to an employment offer and severance agreement with its Chief Medical Officer.

Athira Pharma's Q2 2024 report details financial results and provides updates on clinical trials, including the upcoming topline results for the LIFT-AD trial.

Athira Pharma shifts its focus to ATH-1105 for ALS treatment after Phase 2/3 trial results for fosgonimeton in Alzheimer's disease fall short of statistical significance.

Athira Pharma's 10-K filing outlines the company's stock structure, voting rights, and compliance with securities regulations, while also detailing ongoing clinical trials and risk factors.

Perceptive Advisors LLC, along with related entities and Joseph Edelman, reported the acquisition of stock options for LeonaBio, Inc. (LONA) on April 9, 2026.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund Ltd., reported a stock option grant for 28,000 shares of LionaBio, Inc. common stock.

LeonaBio, Inc. reports that Director Fred Callori was granted stock options for 2,333 shares.

LeonaBio, Inc. reports a Form 4 filing detailing stock option grants to Director Natalie C. Holles.

LeonaBio, Inc. director Peter B. Silverman acquired stock options as part of the company's Outside Director Compensation Policy.

LeonaBio, Inc. reports that Director Michael A. Panzara acquired 28,000 stock options under the company's Outside Director Compensation Policy.

LeonaBio, Inc. calls a Special Meeting to approve significant share issuances related to recent financing and a new equity incentive plan, crucial for advancing its strategic initiatives.

Athira Pharma, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Athira Pharma is asking stockholders to approve a reverse stock split and reduction in authorized shares to meet Nasdaq's minimum bid price requirement and potentially improve stock marketability.

Athira Pharma, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to Section 14(a) of the Securities Exchange Act of 1934.

Athira Pharma announces its 2024 annual meeting of stockholders to be held virtually on May 23, 2024, including proposals for director elections, auditor ratification, and an amendment to limit officer liability.

LeonaBio amends its S-1 filing to register 5.5 million common shares for resale by Sermonix Pharmaceuticals, Inc., generating minimal proceeds for LeonaBio from warrant exercise.

LeonaBio, a clinical-stage biopharmaceutical company, filed an S-1/A to register 58.5 million shares for resale by existing stockholders, with potential proceeds of $146 million from warrant exercises for company operations.

Perceptive Advisors LLC and its affiliates have amended their Schedule 13D filing for LeonaBio, Inc., reporting beneficial ownership of 19.99% and announcing the appointment of Fred Callori to the company's board.

Perceptive Advisors LLC and its affiliates have updated their beneficial ownership in LeonaBio, Inc. to 19.99% of common stock, subject to a beneficial ownership limitation.

Perceptive Advisors and its affiliates have increased their beneficial ownership in Athira Pharma, Inc. to 20.1% following recent stock and warrant acquisitions.

Athira Pharma, Inc. announced a significant private placement led by Perceptive funds and an exclusive licensing agreement for lasofoxifene, involving substantial warrant issuances.

ADAR1 Capital Management and Daniel Schneeberger have filed a Schedule 13G reporting a 7.7% beneficial ownership stake in LeonaBio, Inc.

Baslake Partners, LP, along with its management entity and managing member, reported a passive 1.9% beneficial ownership stake in LeonaBio, Inc. as of December 31, 2025.

Acorn Bioventures and its affiliates, including Anders Hove, have reported a combined beneficial ownership of 6.2% in Athira Pharma, Inc. common stock.

Acorn Bioventures and related entities, including Anders Hove, reported a combined beneficial ownership of 5.2% in Athira Pharma, Inc. common stock.

BML Investment Partners, L.P. and Leonard Braden Michael have reported a 0% beneficial ownership in Athira Pharma Inc.'s common stock.

Baslake Partners, along with Baselake Management and David Paolella, has reported a 5.0% passive ownership stake in Athira Pharma, Inc.